CJC-1295 (No DAC) vs Ipamorelin
Quick Answer
CJC-1295 (No DAC) and Ipamorelin act on different receptors in the somatotropic axis. CJC-1295 (No DAC), also known as Modified GRF (1-29), is a short-acting GHRH analog. Ipamorelin is a selective ghrelin / GH-secretagogue receptor (GHS-R) agonist. They target complementary GH-secretion pathways and are frequently investigated in combination rather than as substitutes. Both are ≥99% HPLC-verified at Peptide.Express for in-vitro research only.
CJC-1295 (No DAC) vs Ipamorelin: At a Glance
| Attribute | CJC-1295 (No DAC) | Ipamorelin |
|---|---|---|
| Receptor target | GHRH receptor | Ghrelin / GHS-R |
| Mechanism class | Short-acting GHRH analog (Mod GRF 1-29) | Selective GH-secretagogue agonist |
| Peptide length | 29 amino acids | 5 amino acids (pentapeptide) |
| CAS number | 863288-34-0 | 170851-70-4 |
| Molecular weight | ~3367.9 Da | ~711.9 Da |
| Commonly studied together | Yes — with Ipamorelin (complementary pathways) | Yes — with CJC-1295 (complementary pathways) |
| Purity (Peptide.Express) | ≥99% HPLC verified | ≥99% HPLC verified |
How CJC-1295 (No DAC) and Ipamorelin Differ in Research
CJC-1295 (No DAC) and Ipamorelin are among the most commonly compared growth-hormone secretagogues, but they are not interchangeable: they act on different receptors. CJC-1295 (No DAC), also called Modified GRF (1-29), is a short-acting GHRH-receptor analog. Ipamorelin is a selective ghrelin-receptor (GHS-R) agonist.
Because they target complementary arms of GH secretion, CJC-1295 and Ipamorelin are more frequently studied together than as alternatives. The combination allows researchers to investigate both the GHRH-receptor pathway and the ghrelin-receptor pathway in somatotropic-axis studies. Ipamorelin is noted for its selectivity with minimal off-target effects in research models.
Peptide.Express supplies both at ≥99% HPLC-verified purity with a Certificate of Analysis. All material is for in-vitro laboratory research and educational use only.
Frequently Asked Questions
Is CJC-1295 the same as Ipamorelin?
No. CJC-1295 (No DAC) is a GHRH analog (Modified GRF 1-29), while Ipamorelin is a selective ghrelin-receptor (GHS-R) agonist. They act on different receptors in the somatotropic axis. For laboratory research use only.
Why are CJC-1295 and Ipamorelin studied together?
They are studied together because they target complementary GH-secretion pathways: CJC-1295 acts on the GHRH receptor, while Ipamorelin acts on the ghrelin receptor. This dual-pathway approach is common in somatotropic-axis research.
Are both available at the same purity?
Yes. Both CJC-1295 (No DAC) and Ipamorelin are HPLC-verified at ≥99% purity with a Certificate of Analysis included with every order from Peptide.Express.